Characteristics and Treatments of Patients Enrolled in the CHAMP‐HF Registry Compared With Patients Enrolled in the PARADIGM‐HF Trial

BACKGROUND: The US Food and Drug Administration approved sacubitril/valsartan for patients with chronic heart failure (HF) with reduced ejection fraction in 2015 on the basis of the results of the PARADIGM‐HF (Prospective Comparison of ARNI [Angiotensin Receptor Neprilysin Inhibitor] With ACEI [Angi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Am Heart Assoc
Main Authors: DeVore, Adam D., Mi, Xiaojuan, Thomas, Laine, Sharma, Puza P., Albert, Nancy M., Butler, Javed, Hernandez, Adrian F., Patterson, J. Herbert, Spertus, John A., Williams, Fredonia B., Duffy, Carol I., McCague, Kevin, Fonarow, Gregg C.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6220559/
https://ncbi.nlm.nih.gov/pubmed/29895587
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.118.009237
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados